# Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency

> **NCT02168686** · PHASE1,PHASE2 · COMPLETED · sponsor: **Adverum Biotechnologies, Inc.** · enrollment: 6 (actual)

## Conditions studied

- Alpha 1-Antitrypsin Deficiency

## Interventions

- **GENETIC:** ADVM-043

## Key facts

- **NCT ID:** NCT02168686
- **Lead sponsor:** Adverum Biotechnologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-28
- **Primary completion:** 2019-08-29
- **Final completion:** 2019-08-29
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2023-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02168686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02168686, "Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02168686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*